Rhumbline Advisers Uro Gen Pharma Ltd. Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Rhumbline Advisers holds 51,293 shares of URGN stock, worth $885,830. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,293

Previous 53,466 4.06%

Holding current value

$885,830

Previous $591,000 18.78%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	SELL	$3.9 - $15.46 $8,474 - $33,594	-2,173 Reduced 4.06%	51,293 $702,000
Q1 2025 Apr 08, 2025	BUY	$9.27 - $12.13 $20,356 - $26,637	2,196 Added 4.28%	53,466 $598,000
Q4 2024 May 29, 2025	SELL	$10.52 - $13.11 $23,101 - $28,789	-2,196 Reduced 4.11%	51,270 $546,000
Q4 2024 Jan 30, 2025	BUY	$10.52 - $13.11 $14,749 - $18,380	1,402 Added 2.81%	51,270 $546,000
Q3 2024 Nov 12, 2024	SELL	$12.7 - $17.92 $7,734 - $10,913	-609 Reduced 1.21%	49,868 $633,000
Q2 2024 Aug 01, 2024	BUY	$12.72 - $19.2 $174,022 - $262,675	13,681 Added 37.18%	50,477 $847,000
Q1 2024 May 09, 2024	BUY	$13.81 - $19.33 $28,862 - $40,399	2,090 Added 6.02%	36,796 $551,000
Q4 2023 Feb 08, 2024	BUY	$10.87 - $15.93 $85,242 - $124,923	7,842 Added 29.19%	34,706 $520,000
Q3 2023 Nov 09, 2023	BUY	$8.84 - $22.64 $57,088 - $146,209	6,458 Added 31.65%	26,864 $376,000
Q2 2023 Aug 08, 2023	BUY	$8.75 - $14.29 $178,552 - $291,601	20,406 New	20,406 $211,000
Q2 2022 Aug 11, 2022	SELL	$5.12 - $8.74 $118,538 - $202,348	-23,152 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$5.92 - $9.73 $5,399 - $8,873	-912 Reduced 3.79%	23,152 $202,000
Q4 2021 Feb 10, 2022	SELL	$9.03 - $19.13 $3,106 - $6,580	-344 Reduced 1.41%	24,064 $229,000
Q3 2021 Nov 12, 2021	BUY	$14.31 - $18.39 $7,226 - $9,286	505 Added 2.11%	24,408 $411,000
Q2 2021 Aug 05, 2021	SELL	$15.2 - $20.94 $40,660 - $56,014	-2,675 Reduced 10.06%	23,903 $365,000
Q1 2021 May 06, 2021	SELL	$17.99 - $26.96 $37,239 - $55,807	-2,070 Reduced 7.23%	26,578 $518,000
Q4 2020 Feb 10, 2021	BUY	$17.54 - $25.43 $54,917 - $79,621	3,131 Added 12.27%	28,648 $516,000
Q3 2020 Nov 12, 2020	SELL	$18.81 - $26.42 $67,151 - $94,319	-3,570 Reduced 12.27%	25,517 $492,000
Q2 2020 Aug 13, 2020	BUY	$16.5 - $29.7 $91,393 - $164,508	5,539 Added 23.52%	29,087 $760,000
Q1 2020 May 06, 2020	BUY	$13.68 - $34.6 $1,956 - $4,947	143 Added 0.61%	23,548 $420,000
Q4 2019 Feb 05, 2020	BUY	$21.11 - $34.86 $29,448 - $48,629	1,395 Added 6.34%	23,405 $781,000
Q3 2019 Oct 23, 2019	BUY	$23.83 - $36.44 $22,185 - $33,925	931 Added 4.42%	22,010 $524,000
Q2 2019 Aug 14, 2019	BUY	$32.75 - $40.35 $690,337 - $850,537	21,079 New	21,079 $758,000

Others Institutions Holding URGN

# of Institutions

161

Shares Held

39.6M

Call Options Held

2.06M

Put Options Held

717K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $393M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Uro Gen Pharma Ltd. Transaction History